Bionomics Ltd ADR — Company Overview, News & Financial Data
Bionomics develops treatments for CNS disorders and cancer, focusing on anxiety, PTSD, and major depressive disorder.
Bionomics Ltd ADR
Company profile
About Bionomics Ltd ADR
Bionomics (NASDAQ:BNOX) focuses on developing treatments for central nervous system disorders and cancer. The company is traded on the NASDAQ under the ticker BNOX. Dedicated to science-driven innovation, Bionomics is deeply involved in the discovery and development of clinical-stage assets. Its prominent projects include BNC210, geared towards treating anxiety, PTSD, and major depressive disorder. By leveraging novel ion channel mechanisms, Bionomics aims to deliver treatments that address significant unmet medical needs. The company is committed to advancing its pipeline and creating transformative therapies that can improve the quality of life for patients worldwide.
Snapshot
-Year founded
8Employees
Adelaide, AustraliaHead office
Loading Map...
Global footprint
Operations
All Locations
Adelaide, AU
Products and/or services of Bionomics Ltd ADR
- BNC210: A lead drug candidate targeting anxiety disorders and PTSD, aiming to show efficacy in reducing anxiety symptoms with minimal side effects.
- Cognition: A research program focused on developing therapies for cognitive impairment associated with aging and other neurological conditions.
- Strategic Partnerships: Collaborations with pharmaceutical companies to co-develop and commercialize novel therapies, enhancing research capabilities and market reach.
- ION Channel Drug Discovery: An initiative leveraging proprietary technology to discover and develop new medications targeting ion channels, crucial for neurological function.
- Biomarker Discovery: Advanced biomarker identification to enhance drug discovery and personalized medicine approaches, improving treatment outcomes for patients.
- Bionomics Clinical Trials: A robust pipeline of clinical trials to evaluate the safety and efficacy of pipeline drugs, supporting regulatory approval and market entry.
Bionomics Ltd ADR executive team
- Dr. Spyridon Papapetropoulos M.D., Ph.D.CEO, President & Director
- Mr. Timothy M. Cunningham CPA, M.B.A.Chief Financial Officer
- Ms. Elizabeth DoolinSenior Vice President of Clinical Development
- Dr. Julie Kerner Ph.D.Senior Vice President of Business Operations
- Dr. Mark A. Smith M.D., Ph.D.Chief Medical Officer
- Mr. Adrian Hinton BEC, F.C.A.Financial Controller
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift